Skip to main content
SpringerLink
Log in
Book cover

Therapeutic Oligonucleotides pp 141–152Cite as

Aptamer–Drug Conjugation for Targeted Tumor Cell Therapy

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 764))

Abstract

Aptamers developed for applications in cancer therapy can improve the efficacy of drug treatment and enhance molecular imaging. Aptamers for these purposes are generated from SELEX (Systematic Evolution of Ligands by EXponential enrichment), more precisely cell-based SELEX, a process described in detail in this chapter. Experimental applications are also provided for aptamer-based drugs.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Tuerk, C., and Gold. L. (1990) Systematic evolution of ligands by exponential enrichment –RNA ligands to bacteriophage-T4 DNA-polymerase. Science 249, 505–510.

    Article  PubMed  CAS  Google Scholar 

  2. Ellington, A. D., and Szostak, J. W. (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818–822.

    Article  PubMed  CAS  Google Scholar 

  3. Xiaohong, F., and Weihong T. (2010) Aptamers generated from Cell-SELEX for molecular medicine: a chemical biology approach. Accounts Chem Res 43, 48–57.

    Article  Google Scholar 

  4. Shangguan, D., Li, Y., Tang, Z. W., Cao, Z. H. C., Chen, H. W., Mallikaratchy, P., Sefah, K., Yang, C. Y. J., and Tan, W. H. (2006) Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Nat Acad Sci USA 103, 11838–11843.

    Article  PubMed  CAS  Google Scholar 

  5. Shamah, S. M., Healy, J. M., and Cload, S. T. (2008) Complex target SELEX. Accounts Chem Res 41, 130–138.

    Article  CAS  Google Scholar 

  6. Shangguan, D., Cao, Z. H., Meng, L., Mallikaratchy, P., Sefah, K., Wang, H., Li, Y., and Tan, W. H. (2008) Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J Proteome Res 7, 2133–2139.

    Article  PubMed  CAS  Google Scholar 

  7. Mallikaratchy, P., Tang, Z. W., Kwame, S., Meng, L., Shangguan, D. H., and Tan, W. H. (2007) Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt’s lymphoma cells. Mol Cell Proteomics 6, 2230–2238.

    Article  PubMed  CAS  Google Scholar 

  8. Lee, J. H., Canny, M. D., De Erkenez, A., Krilleke, D., Ng, Y. S., Shima, D. T., Pardi, A., and Jucker, F. (2005) A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci USA 102, 8902–18907.

    Google Scholar 

  9. Fraunfelder, F. W. (2005) Pegaptanib for wet macular degeneration. Drugs Today 41, 703–709.

    Article  PubMed  CAS  Google Scholar 

  10. Huang, Y-. F., Shangguan, D., Liu, H., Phillips, J. A., Zhang, X., Chen, Y., and Tan, W. (2009) Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. ChemBiochem 10, 862–868.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to extend a special thanks to our colleagues at the University of Florida for their excellent work reported here. This work is supported by NIH grants.

Author information

Authors and Affiliations

  1. Department of Chemistry, Department of Physiology and Functional Genomics, Shands Cancer Center, Moffitt Cancer Center, Center for Research at Bio/Nano Interface, UF Genetics Institute and McKnight Brain Institute, University of Florida, Gainesville, FL, USA

    Michael J. Donovan, Ling Meng, Tao Chen, Yunfei Zhang, Kwame Sefah & Weihong Tan

Authors
  1. Michael J. Donovan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ling Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yunfei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kwame Sefah
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Weihong Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Weihong Tan .

Editor information

Editors and Affiliations

  1. Dept. Chemistry, Worcester State College, Chandler St. 486, Worcester, 01602, Massachusetts, USA

    John Goodchild

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Donovan, M.J., Meng, L., Chen, T., Zhang, Y., Sefah, K., Tan, W. (2011). Aptamer–Drug Conjugation for Targeted Tumor Cell Therapy. In: Goodchild, J. (eds) Therapeutic Oligonucleotides. Methods in Molecular Biology, vol 764. Humana Press. https://doi.org/10.1007/978-1-61779-188-8_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-188-8_9

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-61779-187-1

  • Online ISBN: 978-1-61779-188-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation